mission statement: "Otsuka -- people creating new products
for better health worldwide." Otsuka researches, develops, manufactures and
markets innovative, original products, focusing its core businesses on
pharmaceutical products for the treatment of disease and consumer products
for the maintenance of everyday health. The Otsuka Pharmaceutical Group
comprises 99 companies and employs approximately 31,000 people in 18
countries and regions worldwide. Otsuka and its consolidated subsidiaries
earned US $7.2 billion in consolidated annual revenues in fiscal 2006. For
additional information, please visit http://www.otsuka-global.com
About Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization (OPDC) is a
globally focused organization that plays a leadership role in the research
and development of Otsuka's ethical healthcare products. From initiation of
the clinical program for a compound through high quality clinical studies,
product positioning and global life cycle management, OPDC is the
cornerstone of Otsuka's global drug development and strategic commercial
About Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. (OAPI) is a successful, innovative,
fast-growing healthcare company that commercializes Otsuka-discovered and
other product opportunities in North America, with a strong focus on and
commitment to neuroscience, cardiovascular and gastrointestinal treatments.
OAPI is dedicated to improving patients' health and the quality of human
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka
America Pharmaceutical, Inc. are part of the Otsuka Pharmaceutical Group of
companies. For additional information, please visit http://www.otsuka.com.
PDL BioPharma, Inc. is a biopharmaceutical
Page: 1 2 3 4 Related biology technology :1
|SOURCE Otsuka Pharmaceutical Co., Ltd., and PDL BioPharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration2
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes3
. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results4
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results5
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML6
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20077
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20078
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results9
. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences10
. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer11
. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products